NCT02716142 (RM-SLM) is a Phase 4 clinical trial of rectal misoprostol in Bleeding During Myomectomy, sponsored by Assiut University.

Who is sponsoring NCT02716142?

NCT02716142 is sponsored by Assiut University.

What drugs are being tested in NCT02716142?

Interventions in NCT02716142: rectal misoprostol, sublingual misoprostol.

What condition does NCT02716142 study?

NCT02716142 studies Bleeding During Myomectomy.

Is NCT02716142 still recruiting?

NCT02716142 is currently completed. Last updated 20 May 2020.

Last reviewed 2020-05-20 · How we verify

NCT02716142: RM-SLM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rectal Misoprostol Versus Sublingual Misoprostol Prior to Myomectomy

Completed Phase 4 Last updated 20 May 2020

What this trial tests

Phase 4 trial testing rectal misoprostol in Bleeding During Myomectomy in 80 participants. Completed in 30 April 2020.

Timeline

1 March 2017

Primary endpoint
31 December 2019

30 April 2020

Quick facts

Lead sponsor	Assiut University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	80
Start date	1 March 2017
Primary completion	31 December 2019
Estimated completion	30 April 2020
Sites	1 location across Egypt

Drugs / interventions tested

rectal misoprostol — full drug profile →
sublingual misoprostol — full drug profile →

Conditions studied

Bleeding During Myomectomy — all drugs for Bleeding During Myomectomy →

Sponsor

Assiut University

Who can join

Adults 18 to 50, female only, with Bleeding During Myomectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

the aim of the study is To compare the effectiveness of rectally administered prostaglandin E1 synthetic analogue (misoprostol) 400 microgram versus sublingually administered misoprostol before myomectomy to decrease blood loss during and after the operation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02716142 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 20 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02716142.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing